复方二甲双胍胶囊在健康受试者体内的药物动力学和相对生物利用度

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (6): 623-627.

复方二甲双胍胶囊在健康受试者体内的药物动力学和相对生物利用度

印晓星, 张银娣, 丁黎¹, 沈建平, 李丽敏, 邱俊

南京医科大学临床药理研究所, 南京210029, 江苏;
¹中国药科大学药物分析教研室, 南京210009, 江苏

收稿日期:2004-01-02 修回日期:2004-03-19 发布日期:2020-11-22

Pharmacokinetics and relative bioavailability of compound metformin hydrochloride and glibenclamide capsule in healthy Chinese volunteers

YIN Xiao-Xing, ZHANG Yi-Di, DING Li¹, SHEN Jian-Ping, LI Li-Min, QIU Jun

Institute of Clinical Pharmacology, Nanjing Medical University, Nanjing 210029, Jiangsu, China;
¹Department of Drug Analysis, China Pharmaceutical University, Nanjing 210009, Jiangsu, China

Received:2004-01-02 Revised:2004-03-19 Published:2020-11-22
Contact: ZHANG Yin-Di, corresponding author, female, professor, tutor of doctor,specialized in clinical pharmacology.Tel:025-86863159 Fax:025-86863159 E-mail:ydzhang @njmu.edu.cn
About author:YIN Xiao-Xing, male, associate professor, PhD candidate.E-mail:yinxx@vip.sina.com

摘要/Abstract

摘要： 目的研究复方二甲双胍胶囊在健康受试者体内的药物动力学和相对生物利用度。方法 20 名男性志愿者随机交叉口服复方二甲双胍胶囊(试验药) 或合用二甲双胍片格列本脲片(参比药), HPLC-紫外法和LC-MS 法测定人血浆中二甲双胍和格列本脲浓度, 计算药动学参数和相对生物利用度。结果口服试验药和参比药后二甲双胍的C_max 分别为1.87 ±0.36 和1.77 ±0.35 mg·L^-1;T_max 为1.7 ±0.6和1.8 ±0.5 h;AUC_0-∞ 为8.13 ±1.32 和8.62 ±1.47 mg·L^-1·h^-1, 格列本脲的C_max 分别为129.2 ±51.4 和123.9 ±50.7 μg·L^-1;T_max 为2.3 ±0.7 和2.6 ±0.9 h;AUC_0-∞为0.690 ±0.228 和0.632 ±0.211 mg·L^-1 ·h^-1, 以上参数在试验药和参比药之间皆无显著性差异。试验片中二甲双胍和格列本脲相对于参比药的生物利用度分别为95.0 % ±11.5 % 和109.6 %±8.8 %。结论复方二甲双胍胶囊中二甲双胍和格列本脲与参比药相比皆生物等效。

关键词: 二甲双胍, 格列本脲, 药物动力学, 生物利用度

Abstract: AIM: To compare pharmacokinetics and relative bioavailability of metformin and glibenclamide in compound metformin hydrochloride and glibenclamide capsule (CMGC) with the reference preparations metformin tablet (MT) and glibenclamide tabet (GT). METHODS: Twenty male healthy volunteers were enrolled in a randomized two-way crossover design with a single-oral dose study.The plasma metformin and glibenclamide concentrations were determined by high performance liquid chromatography (HPLC) and liquid chromatography-mass spectrography (LC-MS), respectively.Pharmacokinetics parameters were calculated and bioequivalability was analyzed by two one-side t-test. RESULTS: The pharmacokinetics parameters of metformin in CMGC and co-administration of metformin glinbenclamide were as following, respectively:C_max (1.87 ± 0.36 and 1.77 ±0.35) mg·L ^-1;Tmax (1.7 ±0.6 and 1.8 ±0.5) h;AUC_0-∞(8.13 ±1.32 and 8.62 ±1.47) mg·L ^-1·h ^-1, while those of glinbenclamide were as following, respectively: C_max (129.2 ±51.4 and 123.9 ±50.7) μg·L ^-1;T_max(2.3 ±0.7 and 2.6 ±0.9) h;AUC_0-∞ (0.690 ±0.228 and 0.632 ±0.211) mg·L ^-1·h ^-1.Relative bioavailability of metformin and glibenclamide in CGMC were 95.0 % ±11.5 % and 109.6 %±8.8 %, respectively. CONCLUSION: The main components of CMGC, metformin and glibenclamide, are bioequivalent to the reference tablets, MT and GT.

Key words: metformin, glibenclamide, pharmacokinetics, bioavailability CLC

中图分类号:

R969

印晓星, 张银娣, 丁黎, 沈建平, 李丽敏, 邱俊. 复方二甲双胍胶囊在健康受试者体内的药物动力学和相对生物利用度[J]. 中国临床药理学与治疗学, 2004, 9(6): 623-627.

YIN Xiao-Xing, ZHANG Yi-Di, DING Li, SHEN Jian-Ping, LI Li-Min, QIU Jun. Pharmacokinetics and relative bioavailability of compound metformin hydrochloride and glibenclamide capsule in healthy Chinese volunteers[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(6): 623-627.

参考文献

1 Melander A, Bitzen PO, Faber O, Groop L.Sulphonylurea antidiabetic drugs.An update of their clinical pharmacology and rational therapeutic use[J].Drugs, 1989;37(1):58-72
2 Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus[J].N Engl J Med, 1995;333(9):550-4
3 Lupi R, Marchetti P, Giannarelli R, Coppelli A, Tellini C, Del Guerra S, et al.Effects of glibenclamide and metformin (alone or in combination) on insulin release from isolated human pancreatic islets[J].Acta Diabetol, 1997;34(1):46-8
4 Erle G, Lovise S, Stocchiero C, Lora L, Coppini A, Marchetti P, et al.A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients[J].Acta Diabetol, 1999;36(1-2):61-5
5 Bokhari SU, Gopal UM, DuckworthWC.Beneficial effects of a glyburide metformin combination preparation in type 2 diabetes mellitus[J].Am JMed Sci, 2003;325(2):66-9
6 Hermann LS, Schersté n B, Bitzé n PO, Kjellstrom T, Lindgarde F, Melander A.Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations.A double-blind controlled study[J].Diabetes Care, 1994;17(10):1100-9
7 VasudevanM, Ravi J, Ravisankar S, Suresh B.Ion-pair liquid chromatography technique for the estimation of metformin in its multicomponent dosage forms[J].J Pharm Biomed Anal, 2001; 25(1):77-84
8 Zarghi A, Foroutan SM, Shafaati A, Khoddam A.Rapid determination of metformin in human plasma using ion-pair HPLC [J].J Pharm Biomed Anal, 2003;31(1):197-200
9 Khatri J, Qassim S, Abed O, Abraham B, Al-Lami A, Masood S.A novel extractionless HPLC fluorescence method for the determination of glyburide in the human plasma:application to a bioequivalence study [J].J Pharm Pharmaceut Sci, 2001;4(2):201-6
10 Hsieh S, Selinger K.High-throughput bioananlytical method using automated sample preparton and liquid chromatographyatmospheric pressure ionspray mass spectrometry for quantitative determination of gybenclamide in human serum[J].J Chromatogr B Analyt Technol Biomed Lif Sci, 2002;772(2):347-56
11 Scheen AJ.Clinical pharmacokinetics of metformin[J].Clin Pharmacokinet, 1996;30(5):359-71
12 Groop LC, Luzi L, De Fronzo RA, Melander A.Hyperglycemia and absorption of sulfonylurea drugs[J].Lancet, 1989;2(8655):129-30
13 Whalin-Boll E, Almer LO, Melander A.Bioavailability, kinetics and effects of glipizide in type 2-diabetics[J].Clin Pharmacokinet, 1982;7(4):363-72

[1]	王洁, 李龙, 陈凤, 刘胜菲. 二甲双胍干预肺纤维化发病机制的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 235-240.
[2]	王歆, 刘维英, 武晨, 开锦军, 梁雪杰, 常瑛璇. 二甲双胍调节AMPK/SREBP-1通路及在临床中的应用进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1049-1054.
[3]	王珍, 全海燕, 洪陈亮, 袁李佳龙, 秦旭平. 游泳运动通过促进自噬改善糖尿病小鼠肾功能的研究[J]. 中国临床药理学与治疗学, 2022, 27(6): 632-638.
[4]	郝伟, 左东泽, 张俊秀, 蒋莉莉, 熊莺, 杨解人. 二甲双胍对TGF-β1诱导的大鼠肺泡上皮II型细胞间质转分化的影响[J]. 中国临床药理学与治疗学, 2021, 26(7): 744-752.
[5]	李筱旻, 金浩, 周文智, 杨汉跃, 邹婷, 郭洁, 徐平声. 盐酸二甲双胍缓释片在健康人体的生物等效性研究[J]. 中国临床药理学与治疗学, 2021, 26(4): 408-413.
[6]	李智慧, 刘静彦, 邱雯, 陈红. 氟康唑胶囊在中国健康受试者的人体生物等效性研究[J]. 中国临床药理学与治疗学, 2020, 25(8): 910-915.
[7]	李桂女, 任少琳, 沈瑞明, 季永能, 蔡彩荣, 苏若. 二甲双胍联合糖皮质激素治疗伴糖耐量异常的系统性红斑狼疮患者的临床研究[J]. 中国临床药理学与治疗学, 2020, 25(6): 670-676.
[8]	郭良堂，林超，孙云，戴盛锋，张炳才，陈舒. 二甲双胍对多囊卵巢综合征患者疗效及其对患者脂肪组织miR-25水平的影响[J]. 中国临床药理学与治疗学, 2019, 24(5): 554-560.
[9]	丁秋花，史道华. 二甲双胍抗肿瘤作用的分子机制研究进展[J]. 中国临床药理学与治疗学, 2019, 24(3): 350-354.
[10]	李力，李贺，刘杏娥，魏楠. LC-MS/MS法测定肿瘤患者血浆中阿帕替尼浓度及其临床应用[J]. 中国临床药理学与治疗学, 2018, 23(7): 790-795.
[11]	姚新明，孔祥，赵咏莉，华强，何春玲，余丹，李业琼，戴晓康，叶山东. 二甲双胍抑制高糖培养大鼠肾小球系膜细胞内P38MAPK信号通路与氧化应激[J]. 中国临床药理学与治疗学, 2018, 23(6): 614-620.
[12]	史德军，刘义. 不同剂量二甲双胍对老年2型糖尿病男性患者骨密度和骨代谢的影响[J]. 中国临床药理学与治疗学, 2017, 22(9): 1045-1049.
[13]	宋美情. 二甲双胍对2型糖尿病伴高血压患者骨密度及胰岛素抵抗、细胞因子的影响[J]. 中国临床药理学与治疗学, 2017, 22(6): 694-698.
[14]	李忠洪，王平，周四桂，王桂香. 二甲双胍通过上调谷胱甘肽-S-转移酶μ₂抑制大鼠心肌肥厚[J]. 中国临床药理学与治疗学, 2017, 22(12): 1326-1331.
[15]	赵赢，张娜，庞晓丛，生立嵩，宋俊科，何兰，吕扬，杜冠华. 临床常用普伐他汀钠片大鼠体内药代动力学比较研究[J]. 中国临床药理学与治疗学, 2016, 21(6): 646-652.